Logo

Selexis Signs a Service Agreement with NexImmune to Advance Multiple Immunotherapies for Rare Cancers and Autoimmune Disorders

Share this

Selexis Signs a Service Agreement with NexImmune to Advance Multiple Immunotherapies for Rare Cancers and Autoimmune Disorders

Shots:

  • The companies collaborated to advance two HLAs that can be utilized to broaden therapy options & develops cell lines that target rare cancers and autoimmune diseases
  • NexImmune will use Selexis’ SUREtechnology platform to reduce the time, effort, and costs related to the development of high-performance mammalian cell lines. The HLA IgG4 fusion proteins and T cell co-stimulatory mAb will be produced using Selexis-generated cell lines and added to NexImmune's exclusive AIM injectable nanoparticle technology
  • The agreement supports the development of molecules targeting AML, MM, HPV-associated tumors, and additional HLAs to increase immunotherapy options for patients

Ref: Businessswire | Image: Selexis

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions